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Abstract 
Background: Dipeptidyl Peptidase IV (DPP4/CD26) and Amino Peptidase N (APN/CD13) have essential roles 
in inflammatory diseases. The current study aimed to determine changes in APN and DPP4 enzyme activity in 
the serum and urine of mice with experimental autoimmune encephalomyelitis (EAE). 
Materials and Methods: In the present study, female C57BL/6 mice were studied in two groups (control and 
EAE). Twenty-sevendays after induction, the enzymatic activity of APN and DPP4 in urine and serum samples 
was measured using a spectrophotometric assay. 
Results: The enzyme activity of DPP4 was higher in serum and urine of EAE mice than in the control group 
(mean in serum: 1.04 ± 0.13 pmol/mL and 0.80 ± 0.12 pmol/mL, respectively, P=0.015; mean in urine: 0.26 ± 
0.04 pmol/mL and 0.19 ± 0.04 pmol/mL, respectively, P=0.015). However, the enzymatic activity of APN in 
serum and urine of mice with EAE when compared to the control group had no significant difference (mean 
in serum: 9.20 ± 1.15 unit/mL and 10.25 ± 1.21 unit/mL, respectively, P=0.132, mean in urine: 0.23 ± 0.27 
unit/mL and 0.15 ± 0.05 unit/mL, respectively, P=0.310). 
Conclusion: The increased DPP4 activity along with normal APN activity in urine and serum samples can be 
used as an indicator to detect or follow up on the course of MS disease. Confirmation of this finding needs further 
investigation. 
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Introduction  
Multiple Sclerosis (MS) is a chronic autoimmune 
disease of the central nervous system (CNS) that 
affects more than 2 million people worldwide1. 
Multiple Sclerosis is mainly characterized by 
progressive demyelination and localized inflammation 
in the brain and spinal cord2. While the leading cause of 
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MS is unknown, animal models and patient studies 
have shown that abnormal activity of various types of 
lymphocytes against myelin proteins plays a vital role 
in the pathogenesis of the disease3. 
There is no single diagnostic test for MS; diagnostic 
criteria include both clinical and magnetic resonance 
imaging (MRI) findings that rely on the absence of 
any alternative diagnosis. Therefore, remains a need 
for biomarkers that can be used in both the diagnosis 
and monitoring of MS progression.  
It has previously been shown that aminopeptidase N 
(APN; CD13, E.C. 3.4.11.2) and dipeptidyl peptidase 
IV (DPP4, CD26, EC 3.4.14.5) activity are associated 
with the inflammatory responses in MS4,5, APN is a 
zinc-dependent metallopeptidase of the superfamily of 
gluzincins6 and DPP4 is a 110-kDa transmembrane 
multifunctional serine protease7. APN is involved in 
cell migration, extracellular matrix degradation, and 
antigen processing5 by hydrolyzing a broad spectrum 
of biologically active peptide substrates. APN stops 
hydrolysis if proline is in the second position of the N-
terminal sequence, thus generating potentially DPP4-
susceptible substrates8. Likewise, DPP4 cleaves many 
biologically important substrates, including several 
neuropeptides and chemokines9. DPP4 mainly targets 
glucagon-like peptide, which regulates glucose 
metabolism and is mainly responsible for reducing 
glucose concentrations in the context of type 2 
diabetes mellitus (T2DM).  
APN and DPP4 have a widespread distribution, 
occurring on epithelial cells, fibroblasts, endothelial 
cells, and kidney10. Moreover, APN is expressed by 
monocytes/macrophages, granulocytes, and also 
activated T cells. On the other hand, DPP4 
constitutively is expressed on lymphocytes. Indeed, T 
helper 17 cells that have a pivotal role in MS 
pathology show the highest expression of DPP411. 
APN and DPP4 also exist in soluble form (sAPN and 
sDPP4, respectively), and they are present in different 
biological fluids such as plasma where at least 95% of 
their enzymatic activity is found 12, seminal fluid and 
in low amounts in the cerebrospinal fluid (CSF)13. 
Regarding the pivotal roles of these ectoenzymes, it is 
presumed that the development of inflammatory and 
autoimmune diseases is correlated with the 
disturbances of these molecules' regular activity or 
expression. Hafler et al.14 published the first study that 
showed that the frequency of CD26+ T cells increased 
in the peripheral blood and the CSF of MS patients with 
progressive forms of the disease. Others found that 
CD26 expression decreases somewhat in peripheral 
blood and cerebrospinal fluid after treatment15. 
However, Subsequent studies presented conflicting 
results16, but it was eventually confirmed that 
circulating CD26+ T cells correlate with clinical and 
MRI disease activity scores in MS17,18. Of note, the 
expression of CD13/APN was also found to be 
increased on PBMC in patients with MS19. In recent 
studies, Ziaber et al. presented evidence for APN 
playing a role as an immunological marker of various 
clinical forms of MS. 
Moreover, it has been shown that simultaneous 
inhibition of DPP4 and APN enhances TGF-β 
production and down-regulates T cell functions in the 
central nervous system20. Based on the results of these 
studies, DPP4 and APN enzymatic activity has attracted 
significant interest as a biomarker and a potential 
treatment target of MS21. Soluble DPP4 and APN are 
considered prognostic criteria for several inflammatory 
and autoimmune diseases, including MS (PMID: 
28448874). Prior studies in MS patients or 
experimental autoimmune encephalomyelitis (EAE) 
animal models have focused on the sDPP4 and sAPN 
activity on plasma or CSF. However, the potential 
presence of MS/EAE biomarkers in urine is largely 
neglected. This study aimed to determine plasma and 
urinary activity levels of APN and DPP4 as potential 
biomarkers in EAE. 
Methods 
EAE Induction and Histological evaluation of spinal 
cord tissue: Twelve female C57BL/6 mice (6-8 weeks) 
were obtained from the Royan Research Center of 
Tehran and randomly divided into EAE and control 
groups. Mice were housed and treated according to the 
ethical protocols for animal treatment and handling 
Shahid Beheshti University of Medical Sciences 
(Ethical approval code: 
IR.SBMU.MSP.REC.1396.454).  
To induce EAE, mice were anesthetized by peritoneal 
injection of the combination of 80 μL ketamine 
hydrochloride and 20μL xylazine. 200 μg of the 
MOG35-55 peptide (MOG35–55; KJ Ross-Petersen ApS, 
Copenhagen, Denmark) mixed with the same volume 
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of complete Freund's adjuvant (CFA; Sigma, F5881, 
USA) containing 500 μg of killed Mycobacterium 
tuberculosis (final volume of 100 μL). The injections 
were done subcutaneously in both hind flanks of mice. 
Thirty minutes later, mice have received pertussis 
toxin (300 ng in 100 μL PBS; List Biological Lab, 
Campbell, CA, USA) intraperitoneally.  The injection 
of pertussis toxin was repeated 48h later. 
The clinical symptoms were evaluated every other day 
on a scale from 0 to 7 according to the following 
criteria: 0 = no symptoms; 1 = distal limp tail; 
2 = complete limp tail; 3 = one hind limb paralyzed; 
4 = both hind limbs paralyzed; 5 = Hind limbs and 
one forelimb paralyzed; 6 = Hind limbs and both 
forelimbs paralyzed; 7 = moribund/death22. EAE mice 
were sacrificed 27 days after induction of the disease, 
and spinal cords were removed for histological 
analysis. Infiltration of inflammatory cells and axonal 
destruction are then investigated using standard 
Hematoxylin and Eosin (H&E) and Luxol Fast Blue 
(LFB) staining, respectively23.  
Serum and urine Sample Collection: Urine and 
serum samples of all studied animals were collected 
27 days after induction of the disease. One mL 
of blood sample was collected through retro-
orbital sinuses. All samples were stored at −20°C for 
further use. 
Measurement of CD13/APN and CD26/DPPV 
Enzymatic Activity by Spectrophotometric 
Method: The serum and urine samples were collected 
at the peak of the disease on the 27th day after disease 
induction. The enzymatic activity of CD13/APN was 
measured using a modified method by Behzadi et al.24 
Briefly, 90 µl of substrate mixture [1 mM L-leucine p-
nitro aniline (SIGMA) in methanol] and 10 µl of 
serum were used. Release of p-nitro aniline from L-
leucine p-nitro aniline was measured at a wavelength 
of 405 nm after 60 min using a microplate reader 
(Anthos 2020 UK-Biochrom). The mM extinction 
coefficient of p-nitro aniline at 405 nm is 10.8 nm, so 
APN enzyme activity was calculated using the 
following formula:  
Unit/ml = 
 (A405nm test –A405nm Blank) × (Dilution factor)
 (10.8)(0.1)
. 
DPP4 activity was measured using one mM 
chromogenic substrate Gly-Pro-Gly-Pro-p-
hydrochloride (pNA, Sigma) in 100 mL Tris-HCl pH 
8 buffer25. 10 µL of serum was diluted with 90 µL of 
100 mM Tris-HCl buffer, and then 100 µL of the 
prepared substrate was added to each well and 
incubated at 37°  for 15 min. The reaction was stopped 
by the addition of 1 M sodium acetate buffer at pH 4.4. 
after centrifugation for 5 minutes (10,000 × g), the 
hydrolyzed substrate was measured by optical 
absorption at 405 nm (p-nitro anilide production) using 
an Anthos 2020 microplate reader (Emax, Molecular 
Devices). Negative control of reaction was prepared by 
adding sodium acetate buffer before adding the 
substrate. To determine the concentration of released p-
nitro aniline, a standard curve of p-nitro aniline was 
prepared26. All experiments were repeated three times. 
Statistical analysis: Differences in the mean enzymatic 
activity of APN and DPP4 in the EAE and control 
groups were analyzed by the Mann-Whitney U test, and 
P values ≤ 0.05 were considered statistically significant. 
Data were analyzed by SPSS software (version 21). 
Graph-Pad Prism (GraphPad Software, Inc., San Diego, 
CA version; 6) was used to generate the graphs. 
Results 
Clinical symptoms and Histopathological 
evaluation: Experimental autoimmune 
encephalomyelitis was induced in C57BL/6 mice via 
immunizing them using an emulsion of MOG mixed 
with CFA. Mice showed the first symptoms of the 
disease at 12 ± 1 days after immunization, and the peak 
of the disease was observed 20±3 days after disease 
onset (Figure 1A).  s the disease progressed, the  EAE 
mice loosed their weight (Figure 1B). Twenty-seven 
days after immunization, mice were sacrificed, and 
histological analysis was performed. LFB staining 
together with H&E staining in the spinal cord of EAE 
mice revealed pathology, including large foci of 
degenerating myelin and infiltration of inflammatory 
cells, mostly in the caudal regions of the brain spinal 
cords. The utmost conspicuous changes were observed 
in mice showing the most severe symptoms (clinical 
score 2.0 or greater). (Figure 1C & D). 
Measurement of APN and DPP4 activity: 
Spectrophotometric methods were used to measure the 
activity of APN and DPP4 in serum and urine of the 
EAE and control groups. The urine and serum samples 
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were collected on the 27th-day post-immunization. In 
healthy and EAE mice, the activity of both enzymes 
in the urine samples was lower than their activity in 
sera. 
The level of DPP4 enzyme activity was higher in the 
serum and urine of mice with EAE than in the control 
group (Figure 2A and B). Results showed that the 
mean ± standard deviation (SD) of DPP4 in serum of 
EAE mice was significantly higher than controls (1.04 
± 0.13 pmol/mL and 0.80 ± 0.12 pmol/mL, 
respectively, P = 0.015). Urine analysis revealed that 
DPP4 activity was higher in EAE mice when 
compared to controls (0.26 ± 0.04 pmol/mL and 0.19 
± 0.04 pmol/mL, respectively, P=0.015). However, no 
changes in serum and urinary APN enzyme activity 
were observed in EAE mice when compared with 
health mice (Figure 2C and D).  The mean ± SD of 
serum APN activity in EAE and the control mice was 
9.20 ± 1.15 unit/mL and 10.25 ± 1.21 unit/mL, 
respectively, (P= 0.132). Similarly, urinary activity of 
APN in EAE and controls was 0.23 ± 0.27 unit/mL and 
0.15 ± 0.05 unit/mL, respectively (P = 0.310). 
Discussion 
Most brain disease biomarker studies have focused on 
analyzing CSF and blood samples27. On the other hand, 
most studies on urinary biomarkers have focused on 
kidney diseases due to the close relationship between 
the kidneys and urine28. The lack of attention to urinary 
biomarkers in other diseases, like brain diseases, may 
be because anatomically, the brain and urine are not 
closely related, and also there is the filtering effect of 
the blood-brain barrier and the kidneys. Nevertheless, it 
could be assumed that changes in organs such as the 
 
Figure 1. Clinical signs and body weights of Experimental autoimmune encephalomyelitis mice. (A) Clinical signs were monitored every other 
day by two examiners. EAE signs emerged on the 12th-day post-induction of EAE. (B) The weight of mice was measured every other day. The data 
are the mean ± standard error of the mean (SEM) of six animals per group. (C) Luxol fast blue staining was used to evaluate demyelination in spinal 
cords. Arrows indicate areas of demyelination in one representative image. (D) Haemotoxylin and Eosin staining revealed the area in spinal cords 
that of inflammatory cells infiltrated (arrows depict the area). 
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brain and immune system are somehow reflected in 
the urine. Unlike blood, urine is not subject to 
homeostatic mechanisms. Therefore, more significant 
fluctuations could occur in urine than in blood, better 
reflecting the changes in the human body29. 
Regarding the fact that APN and DPP4  levels and the 
enzyme activity of them increase by inflammatory 
responses in MS/EAE, we examined the activity of 
these two enzymes in urine samples of EAE mice. The 
results of the curresnt study indicated that DPP4 
enzyme activity in serum and urine of EAE mice is 
higher than in the control group, but there is no 
significant difference in APN enzyme activity in 
serum and urine samples of EAE and healthy mice. 
Indeed, enzymatic activity and soluble level of DPP4 
in serum are used as a marker in various chronic 
inflammatory diseases, including diabetes, tumors, 
hematological malignancies, immunological, 
inflammatory, psychoneuroendocrine disorders, viral 
infections, coronary artery disease, cancer,30 and 
asthma31. Additionally, in MS, the elevation of DPP4 
may arise from an increase in the frequency of activated 
T cells in patients, thus reflecting the presence of 
pathogenic myelin-reactive T cells. Previous studies 
showed that the median percentage of CD26+ cells 
among CD4+ T cells and CD8+ T cell populations in 
the peripheral blood of patients with MS were 
increased18. Others found correlations between changes 
in the frequency of CD26-expressing T cells and lesion 
activity in MRI of MS patients with relapsing-remitting 
and chronic progressive disease courses, consistent 
with the function of CD26 in regulating T cell 
activation states17,18. Jensen et al.32 demonstrated that 
the percentage of blood CD26+ CD4+ T cells was 
 
Figure 2. Measurement of DPP4 and APN6 activity in serum and urine samples. Serum and urine samples were collected on the 27th-day post 
disease induction. DPP4 and APN activity was measured using spectrophotometric methods. Mann-Whitney U test was used to analyze differences 
between groups. P values less than 0.05 were considered significant. The data are expressed as the mean ± standard error of the mean (SEM) of six 
mice per group. 
 
Evaluation of the Enzymatic Activity of Soluble CD13/APN and CD26/DPP4 in Serum and …                           Mami et al. 
NBM 183 Novelty in Biomedicine 2021, 4, 178-84 
increased in the initial attack of MS, and correlated 
with disease activity measured by MRI and with 
clinical disease severity. Finally, gene expression 
profiling in MS patients and healthy controls 
identified higher average CD26/DPP4 in peripheral 
blood mononuclear cells of MS patients33. 
Collectively, these data indicate that increased CD26 
expression and enzymatic activity on human CD4+ T 
cells correlates with disease activity in MS.  
Soluble Aminopeptidase N (CD13) is a diagnostic 
biomarker for some malignant34,35 and inflammatory 
diseases36. Additionally, increased expression of APN 
on peripheral blood mononuclear cells in patients with 
MS was reported previously37. However, we did not 
observe significant differences in APN activity in the 
urine and serum of healthy and EAE mice. Since renal 
dysfunction results in a simultaneous increase in APN 
and DPP4 activity38, DPP4 activity and no change in 
APN activity can help differentiate kidney disease 
from EAE/MS. 
Conclusion 
The current study provides evidence that urine may be 
a good source for searching biomarkers of EAE; 
though the current results should be verified by 
subsequent large-scale clinical studies.  
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